---
title: "Bronstein, Gewirtz & Grossman, LLC Encourages GSK plc (GSK) Stockholders to Inquire about Securities Investigation"
description: "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for GSK plc stockholders following a negative FDA advisory vote on GSK's Blenrep treatment. This announcement led to a 4.73% drop i"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251033168.md"
published_at: "2025-07-31T15:00:01.000Z"
---

# Bronstein, Gewirtz & Grossman, LLC Encourages GSK plc (GSK) Stockholders to Inquire about Securities Investigation

> Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for GSK plc stockholders following a negative FDA advisory vote on GSK's Blenrep treatment. This announcement led to a 4.73% drop in GSK's ADR price on July 17, 2025. Investors who purchased GSK securities are encouraged to participate in the investigation by visiting the firm's website. The firm operates on a contingency fee basis, meaning no upfront costs for investors.

NEW YORK CITY, NY / ACCESS Newswire / July 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GSK plc ("GSK" or "the Company") . Investors who purchased GSK securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GSK.

**Investigation Details**

On July 17, 2025, GSK issued a press release announcing "that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations." On this news, GSK's American Depositary Receipt ("ADR") price fell $1.81 per share, or 4.73%, to close at $36.47 per share on July 17, 2025.

**What's Next?**

If you are aware of any facts relating to this investigation or purchased GSK securities, you can assist this investigation by visiting the firm's site: bgandg.com/GSK. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

**There is No Cost to You**

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

**Why Bronstein, Gewirtz & Grossman**

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

**Contact**

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

**SOURCE:** Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

### Related Stocks

- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK - GlaxoSmithKline plc](https://longbridge.com/en/quote/GSK.UK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSK Recieves Approval For Exdensur From The European Commission | GSK plc :GSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSIONGSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | [Link](https://longbridge.com/en/news/276102835.md) |
| GSK Begins Up to GBP450 Million Share Buyback Tranche | GSK Begins Up to GBP450 Million Share Buyback Tranche | [Link](https://longbridge.com/en/news/276103252.md) |
| Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK) | Berenberg Bank analyst Kerry Holford has maintained a Hold rating on GlaxoSmithKline (GSK) with a price target of £20.00 | [Link](https://longbridge.com/en/news/276103203.md) |
| GSK starts GBP450 million buyback tranche as EU approves Exdensur drug | GSK PLC has initiated the fourth tranche of its GBP2 billion buyback program, valued at GBP450 million, expected to conc | [Link](https://longbridge.com/en/news/276127242.md) |
| GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme | British drug major GSK plc has announced the commencement of the fourth tranche of its £2 billion share buyback program, | [Link](https://longbridge.com/en/news/276103384.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.